Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Investor Presentation
Q4 FY22
Investor Presentation
Q4 FY21
Investor Presentation
Q4 FY20
Solara Active Pharma Sciences Ltd (SOLARA) is currently trading at 743.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Solara Active Pharma Sciences Limited is a major manufacturer of active pharmaceutical ingredients (APIs), operating six plants with USFDA and other global regulatory approvals. The company's ibuprofen business, once a major revenue driver, now faces significant challenges due to excess capacity and outdated processes, leading to financial strain. Despite ibuprofen struggles, Solara's non-ibuprofen business shows promise, delivering 25% EBITDA margins and high gross profitability, signaling a strategic pivot towards high-margin APIs. Solara intends to convert some facilities for multipurpose use, including high potent APIs, to mitigate ibuprofen challenges and capitalize on growing niches. The management is pursuing strategic evaluations to potentially divest or revamp the ibuprofen business, aiming for a clearer strategic direction by Q4 2026.
Over the past 52 weeks, Solara Active Pharma Sciences Ltd has traded between a low of ₹422.85 and a high of ₹774.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Solara Active Pharma Sciences Ltd has a market capitalization of approximately 3,595.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Solara Active Pharma Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -2219.30 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,595.27 Cr, Solara Active Pharma Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Solara Active Pharma Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Solara Active Pharma Sciences Ltd is -2219.30. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Solara reported revenue of ₹384.3 crore, EBITDA of ₹63.5 crore, and PAT of ₹16.3 crore for Q1 FY27.
Solara reported Q1 FY27 profit after tax (PAT) of ₹16.3 crore in its Q1’27 earnings update dated July 23, 2026.
The company has scheduled the conference call for July 23, 2026 at 4:00 PM IST to discuss unaudited results for the quarter ended June 30, 2026.
The provided summaries report Q1 revenue at about ₹320 crore (₹320.00 crore and ₹319.15 crore), with roughly 15% quarter-on-quarter growth.
Bearish
4
Neutral
4
Bullish
6
Bearish
4
Neutral
4
Bullish
38
Bearish
0
Neutral
0
Bullish
32
Bearish
4
Neutral
4
Bullish
6
Bearish
4
Neutral
4
Bullish
6
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
440.50 | 4,148 Cr | 46.36 | 5.28 | 0.09 | 12.98 | 12.14 | 6.57 | ||
1144.50 | 3,964 Cr | -38.03 | 5.72 | 0.09 | -10.66 | -6.48 | -9.22 | ||
431.95 | 3,941 Cr | 20.62 | 2.54 | 0.46 | 12.58 | 11.51 | 6.79 | ||
545.25 | 3,841 Cr | 12.60 | 1.41 | 0.00 | 2.88 | 3.79 | 8.15 | ||
3469.95 | 3,606 Cr | 44.49 | 10.90 | 0.00 | 20.31 | 21.46 | 13.69 | ||
743.00 | 3,595 Cr | -2219.30 | 2.86 | 0.00 | -0.12 | 4.81 | -0.07 | ||
374.15 | 3,245 Cr | 56.68 | 2.34 | 0.00 | 3.57 | 4.36 | 3.42 | ||
| Median: 7 Co. | — | 545.25 | 3,841 Cr | 20.62 | 2.86 | 0.00 | 3.57 | 4.81 | 6.57 |
Solara Active Pharma Sciences Limited is a major manufacturer of active pharmaceutical ingredients (APIs), operating six plants with USFDA and other global regulatory approvals.
The company's ibuprofen business, once a major revenue driver, now faces significant challenges due to excess capacity and outdated processes, leading to financial strain.
Despite ibuprofen struggles, Solara's non-ibuprofen business shows promise, delivering 25% EBITDA margins and high gross profitability, signaling a strategic pivot towards high-margin APIs.
Solara intends to convert some facilities for multipurpose use, including high potent APIs, to mitigate ibuprofen challenges and capitalize on growing niches.
The management is pursuing strategic evaluations to potentially divest or revamp the ibuprofen business, aiming for a clearer strategic direction by Q4 2026.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,595 Cr
Low Risk
-2,219.3
37.5
—
2.9
774.00
422.85
Sales CAGR
Profit CAGR
ROE
ROCE
